$36.01+2.21 (+6.54%)
Medline Inc.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and ...
Medline Inc. (NASDAQ:MDLN) is one of the best healthcare stocks to buy with highest upside potential. Barclays cut the price target on Medline Inc. (NASDAQ:MDLN) to $45 from $50 on June 1, maintaining an Overweight rating on the shares. The firm stated that it believes factors such as inflationary pressure weighing on the margin outlook, less […]
Eli Lilly and Natera are among the companies that can keep growing after the artificial-intelligence hype fades. Plus, Five Below’s “squishy dumpling” score.
Medline (NasdaqGS:MDLN) has received a warning letter from the U.S. FDA citing significant repeated violations of current Good Manufacturing Practice regulations. The letter focuses on recurring contamination with B. cereus at Medline drug manufacturing facilities. The FDA action raises concerns about product safety, manufacturing controls, and regulatory compliance at the company. Medline operates in the healthcare products and drug manufacturing space, where quality control and regulatory...
How Medline’s Recent Share Performance Frames Today’s Starting Point Medline (MDLN) has seen its stock decline about 17% over the past month and roughly 26% over the past 3 months, setting a cautious backdrop for investors reviewing the company’s fundamentals and valuation today. See our latest analysis for Medline. With the share price at US$37.01 after a 1 day share price return of a 0.24% decline, the recent 7 day gain contrasts with a weaker 30 day and year to date share price performance...
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.